QIAGEN

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QIAGEN surpasses 2022 targets, eyes growth in diagnostics and biopharma

QIAGEN's strong performance in 2022 exceeded expectations, supported by robust financials and strategic acquisitions.
Despite market challenges, the company remains confident in achieving its 2023 targets, focusing on growth opportunities in diagnostics and biopharma.
Emphasis on innovation, customer knowledge, and strategic shifts position QIAGEN well for sustained growth and leadership in the industry.

QIAGEN surpasses Q1 sales targets, eyes China growth opportunities

QIAGEN's Q1 2023 performance exceeded expectations, with strong sales growth and margin improvements.
The company remains focused on driving growth through product innovation and strategic market expansion.
Challenges include cautious customer spending and evolving market dynamics, particularly in China.
Opportunities lie in capitalizing on strong product performance, investing in new solutions, and expanding market reach.

QIAGEN reports strong Q2 earnings, eyes China growth opportunities

QIAGEN's Q2 performance was solid, driven by key growth areas, but challenges persist with net sales decline and market volatility. The company's strengths in base business sales and focus on growth pillars position it well for future opportunities in China and market expansion.

QIAGEN surpasses Q3 expectations, focuses on sustained growth strategies

QIAGEN's Q3 2023 performance exceeded expectations, showcasing strong financials and strategic leadership changes, with a reaffirmed full-year outlook for 2023.
The company's strengths lie in successful product pillars, sustained growth strategies, and a strategic focus on non-COVID products in key markets.
Challenges include debt repayment impacts, external market uncertainties, and competitive differentiation in expanding product offerings, while opportunities exist in market expansion, innovation, and automation investments.

QIAGEN surpasses Q4 expectations, eyes strategic growth opportunities

QIAGEN's Q4 performance exceeded expectations, showcasing strong growth and profitability.
Challenges include potential risks in Q1 and delays impacting certain product growth.
Strategic investments and upcoming launches present opportunities for continued growth and market expansion.
Overall, QIAGEN's focus on innovation and strategic acquisitions positions them for sustained success in the future.

QIAGEN beats Q1 sales targets, eyes FDA approvals for growth

QIAGEN's Q1 2024 performance exceeded expectations, with strong sales in Diagnostic Solutions. The company reaffirmed its full-year outlook and highlighted advancements in its product portfolio. Despite challenges in the Chinese market, QIAGEN remains focused on growth opportunities and efficient capital allocation.

QIAGEN surpasses Q3 expectations, boosts outlook amid leadership change

QIAGEN delivered strong Q3 results, surpassing expectations and demonstrating improved profitability. Despite leadership changes, the company's strategic initiatives and global positioning bode well for future growth and resilience in the face of market dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

QIAGEN (QGEN) starts commercializing latest test after filing for FDA emergency use authorization (EUA) for symptomatic patients.

QIAGEN (QGEN) Launches COVID-19 Antigen Test With Ellume

Qiagen NV QGEN shares rose in the extended session Wednesday after the Netherlands-based medical diagnostics company said it will begin selling a portable COVID-19 test in the United States. Qiagen shares rose 4% after hours, following a 0.9% rise in the regular session to close at $46.51.

Qiagen stock rises on announced COVID-19 test

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour

QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test That Can Accurately Analyze Over 30 Samples Per Hour

WALTHAM, Mass.--(BUSINESS WIRE)--TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN to develop T cell-based laboratory tests for detecting prior exposure to the novel coronavirus, SARS-CoV-2, using discoveries from TScan's high-throughput TCR/Target discovery platform, T-Scan. Under the terms of the agreement, QIAGEN secures

TScan Therapeutics Announces Partnership with QIAGEN to Develop T Cell-Based Laboratory Test for Comprehensive COVID-19 Immune Response

QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.

QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced it would hold a conference call on Wednesday, October 28, after releasing full results for the third quarter and first nine months of 2020 on Tuesday, October 27. The call is scheduled for 14:00 Frankfurt time / 13:00 London time / 9:00 New York time. It will be hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer. (For Europe: Due to the U

QIAGEN N.V. to hold investor call on Wednesday, October 28, after releasing results for Q3 2020 and first nine months of 2020

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN reports strong results for third quarter and first nine months of 2020 and increases outlook for full-year 2020

QIAGEN Reports Strong Results for Third Quarter and First Nine Months of 2020 and Increases Outlook for Full-Year 2020

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today preliminary sales and adjusted earnings per share (EPS) results for the third quarter of 2020. Net sales grew 26% at actual rates, and also rose 26% at constant exchange rates (CER), to $481.3 million from $382.7 million in the same period of 2019 – a higher rate than the outlook for the third quarter of 2020 for 16-21% CER sales growth announced on July 13, 2020. The better-than-exp

QIAGEN reports strong preliminary results for third quarter of 2020

Is (QGEN) Outperforming Other Medical Stocks This Year?

Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?

The COVID-19 environment may boost Qiagen's (NYSE: QGEN) new products, like QIA-STAT and NeuMoDx, according to BofA Securities. The Qiagen Analyst: Derik de Bruin reinitiated coverage of with a Buy rating and a price target of $59.

BofA Likes Qiagen After Thermo Fisher Deal Fails To Get Shareholder Approval

Abbott Labs

Exact Sciences

Hologic

Thermo Fisher Scientific

Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.

Coronavirus Drives Testing Stocks: Is There Room for More Upside?

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a novel straightforward approach to viral RNA epidemiology that will significantly simplify and accelerate PCR analysis and remove key testing bottlenecks for SARS-CoV-2 and other RNA viruses. QIAGEN’s innovative QIAprep&amp Viral RNA UM Kit combines a liquid-based sample preparation step completed in only two minutes with real-time PCR detection in a stream

QIAGEN to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies and Accelerates PCR Analysis for Research Applications

Flowers Foods

Lakeland Industries

Owens & Minor

Stamps.com

To combat market volatility, create a portfolio of low-beta stocks.

Buy These 5 Low-Beta Stocks to Survive the Choppy Market

Becton, Dickinson and Co.

Fluidigm

Eli Lilly

Luminex

PerkinElmer

QuidelOrtho Corp

You know what they say! To the most sensitive tests go the spoils.

The FDA Just Ranked Coronavirus Tests by Sensitivity. Here's What That Means

Does Qiagen (QGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Qiagen (QGEN) is a Great Momentum Stock to Buy

HCA Healthcare

Surmodics

Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.

3 Stocks to Buy From Strong MedTech Spaces Amid the Pandemic

Is  (QGEN) Outperforming Other Medical Stocks This Year?

Is QIAGEN N.V. (QGEN) Stock Outpacing Its Medical Peers This Year?

QIAGEN (QGEN) expands portfolio of automated testing solutions to address laboratory needs in almost any setting for molecular diagnostics via the completed buyout of NeuMoDx.

QIAGEN (QGEN) Completes Buyout of NeuMoDx, Expands Portfolio

Transaction strengthens QIAGEN’s leadership position in automated molecular testing

QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

Anglogold Ashanti Plc

Barrick Gold

To combat market volatility, it is important to create a portfolio of low-beta stocks.

3 Low-Beta Stocks to Combat Coronavirus-Induced Choppy Market

The surge in new coronavirus infections  broadens the scope for antigen and antibody tests.

Coronavirus Test Makers With Scope to Maximize Investor Benefits

QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.

QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test

In a statement, Qiagen CEO Thierry Bernard added that the antigen tests are meant to supplement, not replace, the molecular, or PCR, tests, which are the most accurate tests on the market.

Qiagen to launch rapid coronavirus test it says could be used in airports and stadiums

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a rapid portable test that can detect SARS-CoV-2 antigens in people with active infections in less than 15 minutes and process on average around 30 swab samples per hour using a small digital detection system.

QIAGEN to Launch Rapid Portable Test That Can Analyze Over 30 Samples Per Hour for SARS-CoV-2 Antigen

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

News for QIAGEN Stock (QGEN)